CYB 003
Alternative Names: CYB-003Latest Information Update: 21 Nov 2024
Price :
$50 *
At a glance
- Originator Cybin
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Preclinical Alcoholism; Psychiatric disorders
Most Recent Events
- 19 Nov 2024 Phase-III clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT06564818)
- 18 Nov 2024 Adverse events and efficacy data from a phase I/IIa trial in major depressive disorder released by Cybin
- 13 Nov 2024 Cybin plans to initiate a CYB003-003 phase III EMBRACE pivotal trial for Major Depressive Disorder in the USA and EU by the first half of 2025